Department of Anesthesiology,Duke University Medical Center, 2301 Erwin Rd, Box #3094, Durham, NC 27710, United States.
Department of Anesthesiology,Duke University Medical Center, 2301 Erwin Rd, Box #3094, Durham, NC 27710, United States.
J Cardiothorac Vasc Anesth. 2022 Oct;36(10):3740-3746. doi: 10.1053/j.jvca.2022.06.022. Epub 2022 Jun 23.
The prediction of right heart failure (RHF) after left ventricular assist device (LVAD) implantation remains a challenge. Recently, risk scores were derived from analysis of the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) data, the EUROMACS-RHF, and the modified postoperative EUROMACS-RHF. The authors assessed the performance characteristics of these 2 risk score formulations in a continuous-flow LVAD cohort at their institution.
A retrospective, observational study.
At a tertiary-care academic medical center.
Adult patients who underwent durable LVAD implantation between 2015 and 2018.
None MEASUREMENTS AND MAIN RESULTS: Early post-LVAD RHF was defined as follows: (1) need for right ventricular assist device, or (2) inotropic or inhaled pulmonary vasodilator support for ≥14 postoperative days. The authors used logistic regression and examined receiver operating characteristic (ROC) curves to evaluate the ability of the 2 risk scores to distinguish between outcome groups. A total of 207 patients met the inclusion criteria. Of the patients, 16% developed RHF (33/207). The EUROMACS-RHF score was not predictive of RHF in the authors' cohort (odds ratio [OR] 1.25; 95% CI [0.99-1.60]; p = 0.06), but the postoperative EUROMACS-RHF CPB score was significantly associated (OR 1.38; 95% CI [1.03-1.89]; p = 0.03). The scores had similar ROC curves, with weak discriminatory performance: 0.601 (95% CI [0.509-0.692]) and 0.599 (95% CI [0.505-0.693]) for EUROMACS-RHF and postoperative EUROMACS-RHF, respectively.
In the authors' single-center retrospective analysis, the EUROMACS-RHF risk score did not predict early RHF. An optimized risk score for the prediction of RHF after LVAD implantation remains an urgent unmet need.
左心室辅助装置(LVAD)植入后右心衰竭(RHF)的预测仍然是一个挑战。最近,风险评分是根据欧洲机械循环支持患者登记处(EUROMACS)数据、EUROMACS-RHF 和改良的术后 EUROMACS-RHF 分析得出的。作者评估了这两种风险评分公式在其机构中的连续流 LVAD 队列中的表现特征。
回顾性观察性研究。
在一家三级保健学术医疗中心。
2015 年至 2018 年间接受耐用型 LVAD 植入的成年患者。
无。
LVAD 后早期 RHF 的定义如下:(1)需要右心室辅助装置,或(2)术后 14 天以上需要正性肌力或吸入性肺血管扩张剂支持。作者使用逻辑回归并检查了受试者工作特征(ROC)曲线,以评估两种风险评分区分结局组的能力。共有 207 名患者符合纳入标准。其中 16%(33/207)的患者发生 RHF。EUROMACS-RHF 评分在作者的队列中不能预测 RHF(比值比 [OR] 1.25;95%置信区间 [CI] [0.99-1.60];p=0.06),但术后 EUROMACS-RHF CPB 评分显著相关(OR 1.38;95% CI [1.03-1.89];p=0.03)。评分的 ROC 曲线相似,具有较弱的鉴别性能:EUROMACS-RHF 为 0.601(95% CI [0.509-0.692]),术后 EUROMACS-RHF 为 0.599(95% CI [0.505-0.693])。
在作者的单中心回顾性分析中,EUROMACS-RHF 风险评分不能预测早期 RHF。优化 LVAD 植入后 RHF 预测的风险评分仍然是一个迫切需要解决的问题。